Cognition Therapeutics, Inc.
NASDAQ: CGTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lisa Ricciardi
- Employees
- 25
- Headquarters
- Purchase, United States
- IPO year
- 2021
- Market cap
- $75.1M
- Website
- https://www.cogrx.com
Loading CGTX…
Loading profile data…Frequently asked questions about CGTX
What does Cognition Therapeutics, Inc. (CGTX) do?
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advance...
Where does CGTX trade?
Cognition Therapeutics, Inc. (CGTX) trades on the NASDAQ Global Market.
What sector is CGTX in?
Cognition Therapeutics, Inc. (CGTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cognition Therapeutics, Inc.?
Lisa Ricciardi is the chief executive officer of Cognition Therapeutics, Inc. (CGTX).
Where is Cognition Therapeutics, Inc. headquartered?
Cognition Therapeutics, Inc. is headquartered in United States.
Does CGTX pay a dividend?
Cognition Therapeutics, Inc. (CGTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CGTX go public?
Cognition Therapeutics, Inc. (CGTX) completed its initial public offering in 2021.